Cytek Biosciences Inc
NASDAQ:CTKB
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.69
9.51
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CTKB stock under the Base Case scenario is 6.58 USD. Compared to the current market price of 6.55 USD, Cytek Biosciences Inc is Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cytek Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CTKB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Cytek Biosciences Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cytek Biosciences Inc
Balance Sheet Decomposition
Cytek Biosciences Inc
Current Assets | 384.1m |
Cash & Short-Term Investments | 277.2m |
Receivables | 44.8m |
Other Current Assets | 62.1m |
Non-Current Assets | 99.6m |
PP&E | 27.4m |
Intangibles | 37.6m |
Other Non-Current Assets | 34.6m |
Current Liabilities | 52.4m |
Accounts Payable | 3.2m |
Accrued Liabilities | 19m |
Other Current Liabilities | 30.2m |
Non-Current Liabilities | 42.2m |
Long-Term Debt | 1.3m |
Other Non-Current Liabilities | 40.9m |
Earnings Waterfall
Cytek Biosciences Inc
Revenue
|
201.2m
USD
|
Cost of Revenue
|
-90.7m
USD
|
Gross Profit
|
110.5m
USD
|
Operating Expenses
|
-134.1m
USD
|
Operating Income
|
-23.6m
USD
|
Other Expenses
|
13.5m
USD
|
Net Income
|
-10.2m
USD
|
Free Cash Flow Analysis
Cytek Biosciences Inc
USD | |
Free Cash Flow | USD |
CTKB Profitability Score
Profitability Due Diligence
Cytek Biosciences Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Cytek Biosciences Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
CTKB Solvency Score
Solvency Due Diligence
Cytek Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Cytek Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTKB Price Targets Summary
Cytek Biosciences Inc
According to Wall Street analysts, the average 1-year price target for CTKB is 8.57 USD with a low forecast of 7.07 USD and a high forecast of 9.45 USD.
Dividends
Current shareholder yield for CTKB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CTKB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
Contact
IPO
Employees
Officers
The intrinsic value of one CTKB stock under the Base Case scenario is 6.58 USD.
Compared to the current market price of 6.55 USD, Cytek Biosciences Inc is Undervalued by 1%.